Table 1.
Antibody-Drug Conjugates approved by the FDA.
| ADC | Target Antigen | Payload | Payload Target | Indication | Approval |
|---|---|---|---|---|---|
| Gemtuzumab ozogamicin (Mylotarg) |
CD33 | Calicheamicin | DNA | CD33+ acute myeloid leukemia | 2000 (withdrawn 2010) re 2017 |
| Brentuximab vedotin (Adcetris) | CD30 | MMAE | Tubulin | Relapsed or refractory and previously untreated stage III/IV Hodgkin lymphoma | 2011 |
| Relapsed or refractory and untreated systemic anaplastic large cell lymphoma | |||||
| Trastuzumab emtansine (Kadcyla) | HER2 | DM1 | Tubulin | HER2+ metastatic breast cancer | 2013 |
| Inotuzumab ozogamicin (Besponsa) | CD22 | Calicheamicin | DNA | Relapsed or refractory B-cell acute lymphoblastic lymphoma | 2017 |
| Moxetumomab pasudotox (Lumoxiti) | CD22 | Pseudomonas exotoxin | eEF-2 | Relapsed or refractory hairy cell leukemia | 2018 |
| Polatuzumab vedotin (Polivy) | CD79b | MMAE | Tubulin | Diffuse large B-cell lymphoma | 2019 |
| Enfortumab vedotin (Padcev) | Nectin-4 | MMAE | Tubulin | Advanced or metastatic urothelial cancer | 2019 |
| Trastuzumab deruxtecan (Enhertu) | HER2 | DXd | DNA (topoisomerase) | Unresectable or metastatic HER2+ and HER2- breast cancer | 2019 |
| Unresectable/metastatic HER2+ non-small cell lung cancer | |||||
| Sacituzumab govitecan (Trodelvy) | Trop-2 | SN-38 | DNA (topoisomerase) | Unresectable or metastatic triple negative breast cancer Advanced or metastatic urothelial cancer |
2020 |
| Belantamab mafodotin (Blenrep) | BCMA | MMAF | Tubulin | Relapsed or refractory multiple myeloma | 2020 (withdrawn 2022) |
| Cetuximab saratolacan (Akalux) | EGFR | IRDye700DX | Cell membrane | Recurrent head and neck cancer | 2020 |
| Loncastuximab tesirine (Zynlonta) | CD19 | SG3199/PBD dimer | DNA | Relapsed or refractory large B-cell lymphoma, diffuse large B-cell lymphoma | 2021 |
| Tisotumab vedotin (Tivdak) | Tissue factor | MMAE | Tubulin | Recurrent or metastatic cervical cancer | 2021 |
| Disitamab Vedotin (Aidixi) | HER2 | MMAE | Tubulin | HER2+ advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) | 2021 |
| HER2+ advanced or metastatic urothelial cancer | |||||
| Mirvetuximab soravtansine (Elahere) | FRα | DM4 | Tubulin | FRα+ platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer | 2022 |
Bold words mean Urinary Tumours.